Table 5.
UROD Activity and Cytosolic Inhibitor | |||||
---|---|---|---|---|---|
mouse | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 | |
Fe-diet | Fe-diet ala/fedex | Fe-diet pcb/ala | Fe-diet pcb/ala/fedex | ||
UROD activity (nmol/mg cytosolic protein/h) | #1 | 0.63 | 0.13 | 0.17 | 0.12 |
#2 | 0.55 | 0.24 | 0.49 | 0.29 | |
#3 | 0.87 | 0.43 | 0.17 | 0.77 | |
#4 | 0.73 | 0.42 | 0.51 | 0.75 | |
#5 | 0.94 | 0.76 | |||
#6 | 0.71 | 0.72 | |||
rhUROD inhibition (%) | #1 | 9.0 | 36.0 | 22.1 | 35.8 |
#2 | 8.0 | 23.3 | 10.7 | 20.3 | |
#3 | 6.6 | 21.0 | 16.6 | 9.4 | |
#4 | 4.1 | 14.0 | 6.7 | 7.2 | |
#5 | 7.7 | 14.6 | |||
#6 | 12.7 | 12.4 |
Mice fed a high iron diet (fe-diet, 2 mg Fe/g) after weaning > 14 weeks and were sacrificed 4 weeks after receiving any of additional treatments indicated. “Fedex” was a single injection of aqueous iron dextran (10 mg, ip), “ala” was δ-aminolevulinic acid (2 mg/ml) provided continuously in the drinking water and “pcb” was a single injection of Aroclor 1254, (4 mg, ip in corn oil). Values for animals are arranged in the same order as the male Cyp1a2−/− Hfe−/− Urod+/− group in Table 2.